UBS Upgrades Boston Scientific (BSX) to Buy
More News related to BSX
- Trading Radar for 02/10: Sprint (S), Dean Foods (DF), Scripps Networks (SNI), Vale S.A. (VALE), Level 3 Comm (LVLT) Report
- Fitch Revises Boston Scientific's Outlook to Stable; Affirms IDR at 'BB+'
- Piper Jaffray Downgrades Boston Scientific (BSX) Following Litigation Settlement with J&J
- Boston Scientific (BSX) Settles Three Patent Disputes with Johnson & Johnson (JNJ); to Pay $1.725B to JNJ
- Cordis Corporation Announces Agreement With Boston Scientific To Resolve Certain Coronary Stent Patent Disputes
More News related to Upgrades
- Soleil Securities Upgrades Zebra Technologies (ZBRA) to Gradually Accumulate; Valuation Call
- UBS Issues Intraday Upgrade on Cimarex Energy (XEC)
- Boenning & Scattergood Upgrades Equinix (EQIX) to Outperform
- Avondale Partners Upgrades ADC Telecommunications (ADCT) to Market Outperform
- Johnson Rice Upgrades Pool Corp (POOL) to Overweight
UBS upgrades Boston Scientific (NYSE: BSX) from Neutral to Buy. Price target increased to $10.
To see all the upgrades/downgrades on shares of BSX, visit our Analyst Ratings page.
Boston Scientific Corporation operates as a developer, manufacturer, and marketer of medical devices used in various interventional medical specialties worldwide.
Related Categories
UpgradesStocks Mentioned
+0.08Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
